Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines

Chemotherapy

Volumn 54, Issue 6, 2008, Pages 463-474

  Xiong, Xishan ^a   Liu, Hong ^b   Fu, Lili ^a   Li, Lin ^a   Li, Jian ^b   Luo, Xiaomin ^b   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AKT; EGFR; Erk1 2; IC50; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; METHYL 2 BENZOATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THIOUREA;

EID: 52849089102     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000159272     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39:1348-1354.
3. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095.
4. Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P: Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J Med Chem 1997;40:3601-3616.
5. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512.
6. Fantl WJ, Johnson DE, Williams LT: Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-481.
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
8. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
10. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528-2533.
11. Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D, Rossi A: Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:758-761.
12. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC: Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol 2006;3:50-57; quiz 51 p following 57.
13. Garfield DH: Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol 2005;23:7738-7740.
14. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T: Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005;44:1165-1177.
15. Tang PA, Tsao MS, Moore MJ: A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006;7:177-193.
16. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155.
17. Li J, Tan JZ, Chen LL, Zhang J, Shen X, Mei CL, Fu LL, Lin LP, Ding J, Xiong B, Xiong XS, Liu H, Luo XM, Jiang HL: Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives. Acta Phar ma col Sin 2006;27:1259-1271.
18. Leung TW, Cheng G, Chui CH, Ho SK, Lau FY, Tjong JK, Poon TC, Tang JC, Tse WC, Cheng KF, Kong YC: Yuehchukene, a bis-indole alkaloid, and cyclophosphamide are active in breast cancer in vitro. Chemotherapy 2000;46:62-68.
19. Chang JS, Chiang LC, Chen CC, Liu LT, Wang KC, Lin CC: Antileukemic activity of Bidens pilosa L var minor (Blume) Sherff and Houttuynia cordata Thunb. Am J Chin Med 2001;29:303-312.
20. Pedro M, Ferreira MM, Cidade H, Kijjoa A, Bronze-da-Rocha E, Nascimento MS: Artelastin is a cytotoxic prenylated flavone that disturbs microtubules and interferes with DNA replication in MCF-7 human breast cancer cells. Life Sci 2005;77:293-311.
21. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K: Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 2007;67:2046-2053.
22. Bai L, Zhu R, Chen Z, Gao L, Zhang X, Wang X, Bai C: Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. Biochem Pharmacol 2006;71:1265-1271.
23. Zhang M, Zhang X, Bai CX, Song XR, Chen J, Gao L, Hu J, Hong QY, West MJ, Wei MQ: Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet Vaccines Ther 2005;3:5.
24. O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP: Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy 2001;47(suppl 2):78-108.
25. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
26. Madhusudan S, Ganesan TS: Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004;37:618-635.